Biocardia Inc. said an independent data safety monitoring board has found there are no safety concerns for the first 10 patients treated in the phase III Cardiamp cell therapy trial. The San Carlos, Calif.-based company’s ongoing multicenter, double-blind, randomized, sham-controlled trial is expected to enroll 260 patients at up to 40 centers across the U.S. and will continue as planned.